Login Register Cart 0
Generic placeholder image

Current Computer-Aided Drug Design

Editor-in-Chief

ISSN (Print): 1573-4099
ISSN (Online): 1875-6697

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Employment of Quality by Design Approach via Response Surface Methodology to Optimize and Develop Modified-release Formulation of Hydrochlorothiazide

Author(s): Vikas D. Singhai, Rahul Maheshwari*, Swapnil Sharma and Sarvesh Paliwal

Volume 17, Issue 2, 2021

Published on: 26 February, 2020

Page: [266 - 280] Pages: 15

DOI: 10.2174/1573409916666200226114517

Price: $65

Abstract

Background: Heart attack predominantly occurs during the last phase of sleep and early morning hours, causing millions of death worldwide. Hydrochlorothiazide (HCTZ) is a recommended drug for the prevention of heart disease, but its long action (>4 h) dosage form is lacking in the commercial market and development of modified-release formulation may have industrial significance. Regulatory agencies emphasize Quality by Design based approach for product development to entrust quality in the product.

Objective: The current research aimed to develop a quality product profile of HCTZ modifiedrelease tablets (MRT; ~14 h) by applying Response Surface Methodology using the computational QbD approach.

Methods: Three independent factors were identified by qualitative and quantitative risk assessment. Statistical terms like p-value, lack of fit, the sum of square, R-squared value, model F value, and linear equations were determined. Graphical tools like normal plot of residual, residual vs predicted plot and box cox plot were used to verify the model selection. The graphical relationship among the critical, independent variables was represented using the Contour plot and 3-D surface plot. Design space was identified by designing an overlay plot using response surface design.

Results: Excellent correlation was observed between actual and predicted values. Similarity Factor (F2) of reproducible trials was 78 and 79, and content uniformity was 100.9% and 100.4%. Average weight, hardness, thickness, diameter, and friability were within acceptable limits.

Conclusion: QbD approach, along with a quality risk management tool, provided an efficient and effective paradigm to build quality MRT of HCTZ.

Keywords: Quality by design, modified release formulation, quality target product profile, heart attack, surface response method, graphical modelS.

« Previous Next »
Graphical Abstract

[1]
Sharma, P.A.; Maheshwari, R.; Tekade, M.; Tekade, R.K.P.; Maheshwari, R.; Tekade, M.; Kumar Tekade, R. Nanomaterial based approaches for the diagnosis and therapy of cardiovascular diseases. Curr. Pharm. Des., 2015, 21(30), 4465-4478.
[http://dx.doi.org/10.2174/1381612821666150910113031] [PMID: 26354926]
[2]
Maheshwari, R.; Tekade, M.; Sharma, P.A.; Tekade, R.K.P.; Kumar Tekade, R. Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders. Curr. Pharm. Des., 2015, 21(30), 4427-4440.
[http://dx.doi.org/10.2174/138161282130151007150300] [PMID: 26471319]
[3]
Mendis, S.; Davis, S.; Norrving, B. Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke, 2015, 46(5), e121-e122.
[http://dx.doi.org/10.1161/STROKEAHA.115.008097] [PMID: 25873596]
[4]
Waeber, B.; Dusing, R.; Glazer, R.; Paldanius, P.; Stricker, K. P1873 Incidence rates of oedema with triple therapy amlodipine/valsartan/HCTZ as compared to valsartan/amlodipine and valsartan/HCTZ dual combination therapy Eur. Heart J., 2018, 39(1)ehy565, P1873.
[5]
Eaton Md, C.B. Combination candesartan-HCTZ did not reduce major CV events in patients at intermediate CV risk. Ann. Intern. Med., 2016, 165(2), JC7.
[http://dx.doi.org/10.7326/ACPJC-2016-165-2-007] [PMID: 27429319]
[6]
Ades, P.A.; Keteyian, S.J.; Wright, J.S.; Hamm, L.F.; Lui, K.; Newlin, K.; Shepard, D.S.; Thomas, R.J. In Increasing cardiac rehabilitation participation from 20% to 70%: a road map from the Million Hearts Cardiac Rehabilitation CollaborativeMayo Clin. Proc; Elsevier, 2017, pp. 234-242.
[7]
Ziegler, M.G.; Milic, M.; Lu, X.; Gharaibeh, M.; Elayan, H. Effect of obstructive sleep apnea on the response to hypertension therapy. Clin. Exp. Hypertens., 2017, 39(5), 409-415.
[http://dx.doi.org/10.1080/10641963.2016.1259327] [PMID: 28557555]
[8]
Maheshwari, R.G.; Thakur, S.; Singhal, S.; Patel, R.P.; Tekade, M.; Tekade, R.K. Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin. Sci. Adv. Mater., 2015, 7(6), 1163-1176.
[http://dx.doi.org/10.1166/sam.2015.2245]
[9]
Pandey, P.K.; Maheshwari, R.; Raval, N.; Gondaliya, P.; Kalia, K.; Tekade, R.K. Nanogold-core multifunctional dendrimer for pulsatile chemo-, photothermal- and photodynamic- therapy of rheumatoid arthritis. J. Colloid Interface Sci., 2019, 544, 61-77.
[http://dx.doi.org/10.1016/j.jcis.2019.02.073] [PMID: 30825801]
[10]
Tekade, R.K.; Maheshwari, R.; Soni, N.; Tekade, M.; Chougule, M.B. Nanotechnology for the Development of Nanomedicine. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes; Academic Press, 2017, pp. 3-61.
[http://dx.doi.org/10.1016/B978-0-12-809717-5.00001-4]
[11]
Mishra, S.M.; Rohera, B.D. An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine. Pharm. Dev. Technol., 2017, 22(7), 889-903.
[http://dx.doi.org/10.1080/10837450.2016.1199566] [PMID: 27346282]
[12]
Mishra, V.; Thakur, S.; Patil, A.; Shukla, A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin. Drug Deliv., 2018, 15(8), 737-758.
[http://dx.doi.org/10.1080/17425247.2018.1504768] [PMID: 30044646]
[13]
Isidori, A.M.; Venneri, M.A.; Graziadio, C.; Simeoli, C.; Fiore, D.; Hasenmajer, V.; Sbardella, E.; Gianfrilli, D.; Pozza, C.; Pasqualetti, P.; Morrone, S.; Santoni, A.; Naro, F.; Colao, A.; Pivonello, R.; Lenzi, A. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol., 2018, 6(3), 173-185.
[http://dx.doi.org/10.1016/S2213-8587(17)30398-4] [PMID: 29229498]
[14]
Yu, L.X.; Amidon, G.; Khan, M.A.; Hoag, S.W.; Polli, J.; Raju, G.K.; Woodcock, J. Understanding pharmaceutical quality by design. AAPS J., 2014, 16(4), 771-783.
[http://dx.doi.org/10.1208/s12248-014-9598-3] [PMID: 24854893]
[15]
Stamatis, D.H. Failure mode and effect analysis: FMEA from theory to execution; ASQ Quality press, 2003.
[16]
Fahmy, R.; Kona, R.; Dandu, R.; Xie, W.; Claycamp, G.; Hoag, S.W. Quality by design I: Application of failure mode effect analysis (FMEA) and Plackett-Burman design of experiments in the identification of “main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets. AAPS PharmSciTech, 2012, 13(4), 1243-1254.
[http://dx.doi.org/10.1208/s12249-012-9844-x] [PMID: 22993122]
[17]
Swapnil Sharma, S.P.; Vikas, D. Singhai, In vitro drug release prediction of hydrochlorothiazide modified release tablet using wagner nelson method and deconvolution approach. Int. J. Pharm. Tech. Res., 2019, 12(01), 49-56.
[http://dx.doi.org/10.20902/IJPTR.2019.120107]
[18]
N, Politis; S, Colombo; P, Colombo; G, M Rekkas D. Design of experiments (DoE) in pharmaceutical development. Drug Dev. Ind. Pharm., 2017, 43(6), 889-901.
[http://dx.doi.org/10.1080/03639045.2017.1291672] [PMID: 28166428]
[19]
Gohel, M.C.; Parikh, R.K.; Aghara, P.Y.; Nagori, S.A.; Delvadia, R.R.; Dabhi, M.R. Application of simplex lattice design and desirability function for the formulation development of mouth dissolving film of salbutamol sulphate. Curr. Drug Deliv., 2009, 6(5), 486-494.
[http://dx.doi.org/10.2174/156720109789941696] [PMID: 19863489]
[20]
Montgomery, D.C. Design and analysis of experiments; John wiley amp sons, 2017.
[21]
Dejaegher, B.; Heyden, Y.V. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J. Pharm. Biomed. Anal., 2011, 56(2), 141-158.
[http://dx.doi.org/10.1016/j.jpba.2011.04.023] [PMID: 21632194]
[22]
Kaur, I.; Tekade, R. Microsponge embedded tablet for sustained delivery of nifedipine. Pharm. Nanotechnol., 2017.
[23]
Advankar, A.; Maheshwari, R.; Tambe, V.; Todke, P.; Raval, N.; Kapoor, D.; Tekade, R.K. Specialized tablets: ancient history to modern developments.Drug Delivery Systems; Elsevier, 2019, pp. 615-664.
[http://dx.doi.org/10.1016/B978-0-12-814487-9.00013-2]
[24]
Ragonese, R.; Macka, M.; Hughes, J.; Petocz, P. The use of the Box-Behnken experimental design in the optimisation and robustness testing of a capillary electrophoresis method for the analysis of ethambutol hydrochloride in a pharmaceutical formulation. J. Pharm. Biomed. Anal., 2002, 27(6), 995-1007.
[http://dx.doi.org/10.1016/S0731-7085(01)00659-8] [PMID: 11836062]

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy